Montelukast to placebo + Placebo to montelukast
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mild Persistent Asthma
Conditions
Mild Persistent Asthma
Trial Timeline
May 1, 2012 → Dec 1, 2015
NCT ID
NCT01581710About Montelukast to placebo + Placebo to montelukast
Montelukast to placebo + Placebo to montelukast is a pre-clinical stage product being developed by Merck for Mild Persistent Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01581710. Target conditions include Mild Persistent Asthma.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01581710 | Pre-clinical | Completed |
Competing Products
20 competing products in Mild Persistent Asthma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Neurosteroid enantiomer | Oragenics | Phase 2 | 44 |
| Ranirestat + Placebo | Eisai | Phase 2/3 | 65 |
| Aricept (donepezil hydrochloride) + placebo | Eisai | Approved | 85 |
| Donepezil HCl | Eisai | Approved | 85 |
| Donanemab + Aducanumab | Eli Lilly | Phase 3 | 77 |
| PPAR alpha + Hydrochlorothiazide + Placebo | Eli Lilly | Phase 2 | 52 |
| Elagolix | AbbVie | Approved | 85 |
| AZD1446 + Placebo | AstraZeneca | Phase 2 | 52 |
| MEDI1814 for IV injection + MEDI1814 for Subcutaneous Injection + IV Placebo + Placebo for Subcutaneous Injection | AstraZeneca | Phase 1 | 33 |
| Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg | AstraZeneca | Approved | 85 |
| AZD5213 + AZD5213 + AZD5213 | AstraZeneca | Phase 2 | 52 |
| budesonide/formoterol (Symbicort) | AstraZeneca | Phase 3 | 77 |
| MK-8931 | Merck | Phase 1 | 33 |
| Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2) | Merck | Phase 3 | 77 |
| Aliskiren + Hydrochlorothiazide + Amlodipine | Novartis | Approved | 85 |
| LCZ696 + Sildenafil | Novartis | Phase 2 | 52 |
| QCZ484 + Placebo | Novartis | Phase 1 | 33 |
| Rivastigmine Patch | Novartis | Approved | 85 |
| AFQ056 | Novartis | Phase 1 | 33 |
| Canakinumab | Novartis | Phase 2 | 52 |